Single-Use Sterility Standards in Hospitals: How Cytology Brushes Market Meets CDC Infection Control Guidelines?

Cytology brushes are small but critical medical devices used to collect cellular samples from hard-to-reach areas of the body for cancer screening and diagnosis. In cervical cancer screening, these brushes gather cells from the cervix during Pap tests or HPV testing, which the CDC recommends starting at age 21. The same instruments are adapted for bronchial brushing in lung cancer evaluation, biliary stricture sampling during ERCP procedures, and endometrial cavity sampling for uterine cancer detection.

NHS England and other healthcare systems are increasingly using plastic cytology brushes because they provide better cellular yield and patient comfort than traditional metal brushes.

Explore the newly updated related study through this free link: https://www.24lifesciences.com/cytology-examination-market-15705

Cervical Screening Program Updates in 2025 and Their Impact on Sample Collection Devices

In July 2025, NHS England changed its cervical screening protocol: women aged 25-49 who test negative for HPV will now be invited every 5 years instead of every 3 years. This policy shift is based on research from King's College London published in The BMJ, which found that 5-yearly screening for HPV-negative women is as safe as 3-yearly screening with no difference in cancer detection rates.

The CDC similarly recommends primary HPV testing every 5 years for women aged 30-65, or co-testing (HPV + Pap) every 5 years. These updated guidelines increase the importance of high-quality cellular sampling, directly affecting demand for cytology brushes that deliver sufficient cell counts for accurate HPV and cytology analysis. The NHS also introduced digital reminders through the NHS App to boost screening uptake, which was at 68.8% for women aged 25-64 in 2023-2024.

Biliary Stricture Diagnosis: Why Brush Cytology Is Combined with Fluoroscopic Biopsy in 2023 ASGE Guidelines

• The American Society for Gastrointestinal Endoscopy (ASGE) released a 2023 clinical practice guideline recommending that fluoroscopic-guided biopsy sampling be used in addition to brush cytology when evaluating biliary strictures of undetermined aetiology.
• This recommendation is based on evidence that brush cytology alone has limited sensitivity for detecting cholangiocarcinoma and other biliary malignancies.
• The guideline emphasises that combining both methods is especially important for hilar strictures, where malignancy risk can reach 55%.
• A 2025 study published in PMC showed that brush-rinse techniques improve diagnostic accuracy for biliary strictures, demonstrating that how the brush is processed matters as much as the brush design itself.
• These clinical protocols directly influence which cytology brushes hospitals purchase; devices must be compatible with ERCP channels and allow effective rinse techniques.

Bronchial Brushing for Lung Cancer: ThinPrep Cytology Shows 87% Sensitivity for Squamous Cell Carcinoma

Lung cancer is often diagnosed at advanced stages, but bronchial brushing cytology offers a minimally invasive diagnostic option during bronchoscopy. A study evaluating ThinPrep (TP) bronchial brushing cytology in 595 patients with suspicious lung cancer found 87.06% sensitivity and 62.93% specificity for lung cancer diagnosis overall. The technique was particularly effective for squamous cell carcinoma (SCC), with 87.44% sensitivity and 90.05% specificity.

For small cell lung carcinoma (SCLC), sensitivity dropped to 61.84%, while adenocarcinoma (ADC) showed 61.04% sensitivity. These findings demonstrate that cytology brushes remain valuable for early lung cancer detection, especially SCC, which is often central and accessible via bronchoscopy. A 2025 JCDR article documented bronchoalveolar lavage combined with bronchial brushing as standard practice at grassroots medical levels in India.

FDA 510(k) Clearance Process for Endoscopic Cytology Brushes: What Manufacturers Must Prove

Medical device manufacturers seeking to market cytology brushes in the United States must submit a 510(k) premarket notification to the FDA to demonstrate substantial equivalence to a legally marketed predicate device.

For example, Zhejiang Chuangxiang Medical Technology Co., Ltd. received 510(k) clearance (K220063) in July 2022 for their Single Use Cytology Brush, classified under gastroenterology/urology with product code FDX. The device is intended for endoscopic use and must be ETO sterile, single-use only, and disposed of according to hospital policy.

Reuse, reprocessing, or re-sterilisation is explicitly prohibited because it may compromise device integrity and cause patient infection or cross-infection. The FDA's 510(k) database shows that new cytology brush clearances continue in 2024-2025, reflecting ongoing innovation in brush geometry, material composition, and compatibility with liquid-based cytology platforms.

Single-Use Sterility and CDC Infection Control: Why Disposable Cytology Brushes Are Mandatory

• CDC's Guideline for Disinfection and Sterilisation in Healthcare Facilities emphasises that single-use devices must never be reused due to infection transmission risks. Cytology brushes are ETO-sterile and packaged with expiration dates; if the sterile package is damaged or the date has lapsed, the device must not be used.
• Reuse creates risk of contamination and transmission of infectious diseases between patients, which can lead to patient injury, illness, or death.
• This is particularly critical in endoscopy, where endoscope-transmitted infections have emerged as a serious concern globally.

The shift toward disposable cytology brushes in outpatient settings reflects both infection control requirements and cost management strategies, as single-use options eliminate reprocessing costs and reduce liability.